Firefly Neuroscience, Inc. AIFF
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -14.77%
- 1 year
- -50.33%
5D -0.0874 (-8.74%)
- Market cap
- 11.81M
- Revenue (ttm)
- 64.00K
- EPS (ttm)
- -0.45
- Shares out
- 8.50M
- YTD return
- -14.77%
- 1-year return
- -50.33%
- Volume
- 80.35K
- Avg volume
- 2.66M
- Open
- 0.815
- Previous close
- 0.83
- Day's range
- 0.7406 – 0.8228
- 52-week range
- 0.64 – 3.02
Key statistics
- 50-day average
- 3.15
- 200-day average
- 5.61
- Enterprise value
- 26.48M
- Price / sales
- 337.48
- Price / book
- 846.67
- Revenue growth
- -97.80%
- Total cash
- 358.00K
- Total debt
- 175.00K
Fundamental scorecard
9 of 25 checks passed on AIFF’s reported financials
9of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
About Firefly Neuroscience, Inc.
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.
- Sector
- Technology
- Industry
- Software - Application
- Country
- Canada
- Website
- fireflyneuro.com
News
Firefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans as Commercial Expansion Accelerates
12 Health Care Stocks Moving In Tuesday's After-Market Session Firefly Neuroscience's Versus Platform Now Commercially Available For EEG Testing
Firefly Neuroscience (NASDAQ: AIFF) Strengthens Non-Invasive Brain-Computer Interface Growth Strategy with Commercially Available Versus Platform
Definitive Healthcare (NASDAQ:DH) versus Firefly Neuroscience (NASDAQ:AIFF) Financial Comparison
Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care
Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD
Firefly Neuroscience's Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial's AI-Native Operating System for Brain Medicine
Firefly Neuroscience (NASDAQ:AIFF) vs. Pro Medicus (OTCMKTS:PMCUF) Head-To-Head Analysis
Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
Your note
Sign in to keep a note on AIFF — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENOIT GERALD JAMES JR | Chief Executive Officer | Purchase | Sep 28, 2023 | 1,985,780 |
| JOHNSON DAVID IAN | Officer and Director | Stock Award(Grant) | Oct 21, 2024 | 557,885 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.67% | 57,358 | 145.69K | Sep 29, 2024 |
| Millennium Management Llc | 0.67% | 56,934 | 144.61K | Sep 29, 2024 |
| Waldron Private Wealth LLC | 0.14% | 12,000 | 30.48K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.02% | 1,304 | 3.31K | Sep 29, 2024 |
| Wells Fargo & Company | 0.01% | 687 | 1.74K | Sep 29, 2024 |
| Wexford Capital LP | 0.01% | 961 | 2.44K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.39% | 33,383 | 84.79K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 11,271 | 28.63K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 7,881 | 20.02K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.04% | 3,699 | 9.39K | Sep 29, 2024 |
